Literature DB >> 8942417

Large daily fluctuations in plasma tyrosine in treated patients with phenylketonuria.

F J van Spronsen1, T van Dijk, G P Smit, M van Rijn, D J Reijngoud, R Berger, H S Heymans.   

Abstract

In patients with phenylketonuria (PKU), extra tyrosine supplementation is advocated in addition to tyrosine-enriched amino acid mixtures. PKU patients have low fasting plasma tyrosine concentrations, but little is known about tyrosine fluctuations during the day. Plasma tyrosine concentrations were studied in 12 PKU patients in response to a test without breakfast and to three tests with different tyrosine contents in breakfast and lunch: 0%/30%, 25%/30%, 50%/10%, and 75%/10% tests, reflecting the protein consumption at breakfast and lunch, respectively. Prolonged fasting resulted in a small decrease in the already low overnight fasting plasma tyrosine concentrations. Breakfast and lunch with 25% and 30% of the daily tyrosine intake resulted in both lower than normal and higher than normal tyrosine concentrations. The 50%/10% and 75%/10% tests resulted in excessively high plasma tyrosine concentrations in most patients. Therefore, both lower than normal and higher than normal postprandial plasma tyrosine concentrations were found in treated PKU patients, even if the daily tyrosine intake was distributed evenly. When there was a large fractional tyrosine intake from one meal, very high plasma tyrosine concentrations were found. Therefore, strict control of plasma tyrosine is necessary if tyrosine supplementation is considered in addition to the tyrosine-enriched amino acid mixtures.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8942417     DOI: 10.1093/ajcn/64.6.916

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  15 in total

1.  Maternal phenylketonuria: low phenylalaninemia might increase the risk of intra uterine growth retardation.

Authors:  Raphaël Teissier; Emmanuel Nowak; Murielle Assoun; Karine Mention; Aline Cano; Alain Fouilhoux; François Feillet; Hélène Ogier; Emmanuel Oger; Loïc de Parscau
Journal:  J Inherit Metab Dis       Date:  2012-06-05       Impact factor: 4.982

2.  Plasma phenylalanine is associated with decreased serum ubiquinone-10 concentrations in phenylketonuria.

Authors:  R Artuch; C Colomé; M A Vilaseca; C Sierra; F J Cambra; N Lambruschini; J Campistol
Journal:  J Inherit Metab Dis       Date:  2001-06       Impact factor: 4.982

3.  What Is the Best Blood Sampling Time for Metabolic Control of Phenylalanine and Tyrosine Concentrations in Tyrosinemia Type 1 Patients?

Authors:  Esther van Dam; Anne Daly; Gineke Venema-Liefaard; Margreet van Rijn; Terry G J Derks; Patrick J McKiernan; M Rebecca Heiner-Fokkema; Anita MacDonald; Francjan J van Spronsen
Journal:  JIMD Rep       Date:  2017-01-25

4.  Tyrosinyl-amantadine: A New Amantadine Derivative With an Ameliorative Effect in a 6-OHDA Experimental Model of Parkinson's Disease in Rats.

Authors:  Maria Lazarova; Lyubka Tancheva; Radoslav Chayrov; Elina Tzvetanova; Albena Alexandrova; Andrey Popatanasov; Diamara Uzunova; Miroslava Stefanova; Ivanka Stankova; Reni Kalfin
Journal:  J Mol Neurosci       Date:  2022-01-28       Impact factor: 3.444

5.  A different approach to breast-feeding of the infant with phenylketonuria.

Authors:  Margreet van Rijn; Jolita Bekhof; Tietie Dijkstra; Peter G P A Smit; Pim Moddermam; Francjan J van Spronsen
Journal:  Eur J Pediatr       Date:  2003-03-04       Impact factor: 3.183

6.  A preliminary report on dopamine system reactivity in PKU: acute effects of haloperidol on neuropsychological, physiological, and neuroendocrine functions.

Authors:  Monica Luciana; Karen L Hanson; Chester B Whitley
Journal:  Psychopharmacology (Berl)       Date:  2004-03-13       Impact factor: 4.530

Review 7.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

8.  People are different: tyrosine's modulating effect on cognitive control in healthy humans may depend on individual differences related to dopamine function.

Authors:  Bryant J Jongkees; Bernhard Hommel; Lorenza S Colzato
Journal:  Front Psychol       Date:  2014-10-06

Review 9.  Phenylketonuria: dietary and therapeutic challenges.

Authors:  M Giovannini; E Verduci; E Salvatici; L Fiori; E Riva
Journal:  J Inherit Metab Dis       Date:  2007-03-08       Impact factor: 4.750

10.  Evaluation of Tetrahydrobiopterin Therapy with Large Neutral Amino Acid Supplementation in Phenylketonuria: Effects on Potential Peripheral Biomarkers, Melatonin and Dopamine, for Brain Monoamine Neurotransmitters.

Authors:  Shoji Yano; Kathryn Moseley; Xiaowei Fu; Colleen Azen
Journal:  PLoS One       Date:  2016-08-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.